Albert Einstein College of Medicine, Department of Medical Oncology, Montefiore Medical Center, Bronx, NY 10467, USA.
Crit Rev Oncol Hematol. 2012 Jul;83(1):47-58. doi: 10.1016/j.critrevonc.2011.08.006. Epub 2011 Sep 23.
Colorectal Cancer is the second most common cancer in incidence and mortality in the United States. In spite of current screening strategies 1 out of 5 patients still presents with metastatic disease. During the last 10-15 years there has been significant increase in the availability of chemotherapy options for this disease. The recent introduction of molecular markers to the treatment algorithm allows oncologists to tailor treatments for each particular patient. In the following article we give an overview of the landmark publications that led to our current standards and we give our view on particular situations in which the available evidence is not so helpful in making therapeutic decisions.
结直肠癌是美国发病率和死亡率第二高的癌症。尽管目前有筛查策略，但仍有 1/5 的患者出现转移性疾病。在过去的 10-15 年中，这种疾病的化疗选择显著增加。最近，分子标志物被引入治疗算法，使肿瘤学家能够根据每个患者的具体情况定制治疗方案。在本文中，我们概述了导致目前标准的重要出版物，并就现有证据在做出治疗决策方面帮助不大的特定情况发表了我们的看法。
